Chronic hepatitis in kidney allograft recipients.
98 HBsAg-positive and 31 HBsAg-negative kidney recipients were compared to assess the effect of renal transplantation on chronic liver disease and vice versa. Diagnosis was based on analysis of liver biopsy specimens including semiquantitative evaluation of histological features of chronic hepatitis. Serial specimens were examined: chronic liver disease occurred in 88% of HBsAg-positive patients and 4% of HBsAg-negative patients with normal liver at the time of transplantation. Liver abnormalities in the former were chronic persistent hepatitis (32%), chronic active hepatitis (51%), and cirrhosis (17%). Actuarial patient survival was similar in HBsAg-positive (78%) and HBsAg-negative (87%) patients, as was allograft survival (64% and 71%, respectively). In both HBsAg-positive and HBsAg-negative patients chronic alcohol consumption was more frequent in those with chronic liver disease than those without. These data suggest that renal transplantation may be appropriate for haemodialysis patients with chronic hepatitis whatever their HBV status.
Pol
S
S
Départment de Néphrologie Adulte, Hôpital Necker, Paris.
Debure
A
A
Degott
C
C
Carnot
F
F
Legendre
C
C
Brechot
C
C
Kreis
H
H
D000206:Actuarial Analysis; D000328:Adult; D001706:Biopsy; D016009:Chi-Square Distribution; D005069:Evaluation Studies as Topic; D005260:Female; D006085:Graft Survival; D006510:Hepatitis B Antibodies / Q000032:analysis*; D006514:Hepatitis B Surface Antigens / Q000276:immunology*; D006521:Hepatitis, Chronic / Q000150:complications / Q000209:etiology / Q000401:mortality / Q000473:pathology*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D016030:Kidney Transplantation / Q000009:adverse effects / Q000401:mortality; D008099:Liver / Q000473:pathology*; D008104:Liver Cirrhosis, Alcoholic / Q000150:complications / Q000401:mortality / Q000473:pathology*; D008297:Male; D012720:Severity of Illness Index; D014184:Transplantation, Homologous
D006510:Hepatitis B Antibodies; D006514:Hepatitis B Surface Antigens; D007166:Immunosuppressive Agents